Fractyl Health, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $60.7M
- Price
- $4.58
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.11%
- Volume
- 43.6K
About
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Quick stats
Shares outstanding13.3M
Computed float10.1M
Float / shares76.4%
Cash runway (months)3.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001572616
Websitehttps://fractyl.com
AI Summary
AI-generated1/50
minorneutrallegal litigation
Recover Investment Losses: Class Action Initiated Against Fractyl Health, Inc. (GUTS)
A securities class action has been filed against Fractyl Health on behalf of investors who purchased GUTS shares between January 13, 2025 and January 29, 2026.
The complaint alleges defendants overstated Revita's efficacy and that operational issues at REMAIN-1 Midpoint Cohort clinical sites may have compromised trial results, making public statements materially misleading.
The notice was issued by plaintiff firm Levi & Korsinsky to solicit affected shareholders; treat as moderate-signal given the real litigation risk around the company's lead asset.
Red flags
- securities fraud allegations concerning integrity of Revita REMAIN-1 clinical trial data
- alleged misstatements about lead asset's clinical, regulatory, and commercial prospects